Search This Blog

Monday, December 23, 2019

Regeneron’s Ebola treatment gets orphan status

The FDA grants orphan drug status to Regeneron’s (REGN -0.3%) atoltivimab, odesivimab, and maftivimab, a post-exposure prophylaxis against Ebola virus infection.
FDA reference link.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)